Naloxegol Oxalate Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 12.5 mg, 25 mg

Reference Brands: Movantik (USA), Moventig (EU)

Category: Gastrointestinal Drugs

Naloxegol oxalate is a peripherally acting μ‑opioid receptor antagonist used to treat opioid‑induced constipation in adults with chronic non‑cancer pain who have not responded adequately to laxatives. It is a PEGylated derivative of naloxone designed to act mainly in the gastrointestinal tract without affecting central pain relief. Naloxegol is taken orally once daily, usually on an empty stomach. Available in 12.5 mg and 25 mg tablets, it helps improve bowel movement frequency. Common side effects include abdominal pain, diarrhea, nausea, flatulence, and headache. Naloxegol oxalate is available in Tablets and strengths such as 12.5 mg, 25 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Naloxegol oxalate is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Naloxegol oxalate can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Naloxegol oxalate is an orally active gastrointestinal drug belonging to the class of peripherally acting μ‑opioid receptor antagonists (PAMORAs), specifically designed to treat opioid‑induced constipation (OIC) in adult patients with chronic non‑cancer pain who have had an inadequate response to traditional laxatives. Because it is a PEGylated derivative of naloxone, naloxegol has significantly reduced ability to cross the blood‑brain barrier, so it preferentially blocks opioid receptors in the gastrointestinal tract without interfering with the central analgesic effects of opioids. This selectivity helps restore normal bowel function by counteracting the opioid‑induced slowing of gastrointestinal motility while maintaining pain control. Naloxegol is available in tablets of 12.5 mg and 25 mg, taken once daily on an empty stomach. In the United States, it is marketed under the brand Movantik, and in the European Union and United Kingdom, it is marketed as Moventig. The dosing may be adjusted for patients with renal impairment, and treatment should be discontinued if opioid therapy is stopped. Common side effects include abdominal pain, diarrhea, nausea, flatulence, vomiting, and headache, generally mild to moderate in severity.